Clinical Trial Update: A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202 [Phase 2]

View source ↗

Summary

Phase 2 platform trial GALAXIES H&N-202 evaluating novel immunotherapy combinations as first-line treatment for PD-L1 positive recurrent/metastatic squamous cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Head and Neck | Phase 2 | Status: ACTIVE_NOT_RECRUITING